Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Other Non Operating Income (2020 - 2025)

Historic Other Non Operating Income for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $705000.0.

  • Tango Therapeutics' Other Non Operating Income fell 6395.71% to $705000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 4918.25%. This contributed to the annual value of $7.6 million for FY2024, which is 2804.51% up from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Other Non Operating Income is $705000.0, which was down 6395.71% from $910000.0 recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Other Non Operating Income peaked at $2.2 million during Q1 2024, and registered a low of -$81000.0 during Q4 2021.
  • Over the past 5 years, Tango Therapeutics' median Other Non Operating Income value was $967000.0 (recorded in 2022), while the average stood at $920421.1.
  • As far as peak fluctuations go, Tango Therapeutics' Other Non Operating Income tumbled by 415000.0% in 2021, and later surged by 268936.17% in 2023.
  • Tango Therapeutics' Other Non Operating Income (Quarter) stood at -$81000.0 in 2021, then skyrocketed by 1293.83% to $967000.0 in 2022, then soared by 113.13% to $2.1 million in 2023, then fell by 28.38% to $1.5 million in 2024, then plummeted by 52.24% to $705000.0 in 2025.
  • Its last three reported values are $705000.0 in Q3 2025, $910000.0 for Q2 2025, and $1.1 million during Q1 2025.